Supriya Lifescience Ltd

Supriya Lifescience: Revenue at ₹827.9 Cr, 10-yr CMO deal & ₹1,000 Cr milestone in sight 📈

- 10-year CMO contract with European pharma: ₹600 million/year from FY27

- Revenue milestone ₹1,000 crore within sight for FY26-27

- Revenue from operations ₹827.9 crore, up 18.9% YoY

- EBITDA grew 12.8% to ₹294.1 crore, margin 35.5%

- Profit after tax ₹209.1 crore, up 11.2% YoY

- Capacity expanded to 932 KLPD with Module E commissioning

- Exports contributed 82% of revenues; Europe 40%

- Backward-integrated products 76% of revenue

- Top 10 customers contributed 52% of revenue

- Capital expenditure ₹152 crore towards Ambernath and other expansions